SCHEMBL4159323

SCHEMBL4159323

CS(=O)(=O)c1cccc(-c2cc3c(cc2Cl)[nH]c(=O)c2[nH]cc(CCC(=O)O)c23)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.45
GPR17 Q13304 1/20 0.40
PRKAG1 P54619 7/20 0.38
PRKAA2 P54646 7/20 0.38
PRKAB1 Q9Y478 7/20 0.38
PRKAB2 O43741 5/20 0.37
PRKAA1 Q13131 5/20 0.37
PRKAG3 Q9UGI9 5/20 0.37
PRKAG2 Q9UGJ0 5/20 0.37
S1PR1 P21453 4/20 0.35
PTGER3 P43115 3/20 0.35
F7 P08709 1/20 0.34
PTGER1 P34995 2/20 0.34
PTGER4 P35408 2/20 0.34
PTGER2 P43116 2/20 0.34
CAMKK2 Q96RR4 1/20 0.34
EIF4A3 P38919 1/20 0.33
GRK6 P43250 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155339 0.87 CAMKK2 (0.40) FASNGPR17S1PR1PTGER3F7
SCHEMBL3249044 0.85 PRKAG1 (0.48) FASNPRKAG1PRKAA2PRKAB1PRKAB2
SCHEMBL4153846 0.81 CAMKK2 (0.39) FASNS1PR1F7CAMKK2GRK6
SCHEMBL3252420 0.80 FASN (0.44) FASNPRKAG1PRKAA2PRKAB1PRKAB2
Propionic Acid SCHEMBL4159324 0.79 FASN (0.48) FASNPRKAG1PRKAA2PRKAB1PRKAB2
SCHEMBL3241835 0.79 FASN (0.43) FASNPRKAG1PRKAA2PRKAB1PRKAB2
SCHEMBL4157978 0.78 HPGD (0.39) GPR17S1PR1F7
SCHEMBL4155187 0.78 HPGD (0.38) GPR17
SCHEMBL13950957 0.77 FASN (0.44) FASNPRKAG1PRKAA2PRKAB1PRKAB2
SCHEMBL4155350 0.76 GPR17 (0.46) GPR17PRKAG1PRKAA2PRKAB1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 FASN 2527/4885GPR17 2461/4885PRKAG1 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.